Observed drug-receptor association rates are governed by membrane affinity: The importance of establishing "micro-pharmacokinetic/pharmacodynamic relationships" at the β2-adrenoceptor

Molecular Pharmacology

Volumn 85, Issue 4, 2014, Pages 608-617

  Sykes, David A ^a   Parry, Cheryl ^a   Reilly, John ^b   Wright, Penny ^a   Fairhurst, Robin A ^b   Charlton, Steven J ^a  

^a Novartis Institutes for Biomedical Sciences   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CYANOPINDOLOL; DRUG RECEPTOR; FORMOTEROL; ISOPRENALINE; LABETALOL; METOPROLOL; NADOLOL; PHOSPHOLIPID; PROPRANOLOL; SALBUTAMOL; SALMETEROL; SOTALOL; TIMOLOL; TIMOLOL MALEATE;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MOLECULAR INTERACTION; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LIGANDS; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; PHOSPHOLIPIDS; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84896868515     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.090209     Document Type: Article

References (31)

1. Affolter H, Hertel C, Jaeggi K, Portenier M, and Staehelin M (1985) (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci USA 82:925-929. (Pubitemid 15142790)
2. Audet M and Bouvier M (2008) Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol 4:397-403. (Pubitemid 351860553)
3. Avdeef A, Box KJ, Comer JE, Hibbert C, and Tam KY (1998) pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm Res 15:209-215. (Pubitemid 28144231)
4. Baur F, Beattie D, Beer D, Bentley D, Bradley M, Bruce I, Charlton SJ, Cuenoud B, Ernst R, and Fairhurst RA et al. (2010) The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. J Med Chem 53:3675-3684.
5. Carter CM, Leighton-Davies JR, and Charlton SJ (2007) Miniaturized receptor binding assays: complications arising from ligand depletion. J Biomol Screen 12:255-266. (Pubitemid 46364429)
6. Castanho MA and Fernandes MX (2006) Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the "membrane catalysis" model. Eur Biophys J 35:92-103. (Pubitemid 43045700)
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. García-Sosa AT, Hetényi C, and Maran U (2010) Drug efficiency indices for improvement of molecular docking scoring functions. J Comput Chem 31:174-184.
9. Green SA, Spasoff AP, Coleman RA, Johnson M, and Liggett SB (1996) Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 271:24029-24035.
10. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, Desale H, Clemons B, Cahalan SM, and Schuerer SC et al. (2012) Crystal structure of a lipid G proteincoupled receptor. Science 335:851-855.
11. Herbette LG, Vant Erve YM, and Rhodes DG (1989) Interaction of 1, 4 dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors. J Mol Cell Cardiol 21:187-201. (Pubitemid 19111208)
12. Hildebrand PW, Scheerer P, Park JH, Choe HW, Piechnick R, Ernst OP, Hofmann KP, and Heck M (2009) A ligand channel through the G protein coupled receptor opsin. PLoS ONE 4:e4382.
13. Hoyer D, Engel G, and Berthold R (1982) Binding characteristics of (+)-, (+/-) - and (-)-[125iodo] cyanopindolol to guinea-pig left ventricle membranes. Naunyn Schmiedebergs Arch Pharmacol 318:319-329. (Pubitemid 12135730)
14. Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, and Gilles RW et al. (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18:4872-4875.
15. Hurst DP, Grossfield A, Lynch DL, Feller S, Romo TD, Gawrisch K, Pitman MC, and Reggio PH (2010) A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem 285:17954-17964.
16. Jiang Z, Reilly J, and Everatt B (2008) A method for rapidly predicting drug tissue distribution using surfactant vesicle electrokinetic chromatography. Electrophoresis 29:3674-3684.
17. Kerns EH, Di L, Petusky S, Kleintop T, Huryn D, McConnell O, and Carter G (2003) Pharmaceutical profiling method for lipophilicity and integrity using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 791:381-388. (Pubitemid 36638771)
18. Leeson PD and Springthorpe B (2007) The influence of drug-like concepts on decisionmaking in medicinal chemistry. Nat Rev Drug Discov 6:881-890. (Pubitemid 350042396)
19. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26. (Pubitemid 33653411)
20. Mason RP, Rhodes DG, and Herbette LG (1991) Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 34:869-877.
21. McCloskey MA and Poo MM (1986) Rates of membrane-associated reactions: reduction of dimensionality revisited. J Cell Biol 102:88-96. (Pubitemid 16155556)
22. Motulsky HJ and Mahan LC (1984). The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25:1-9. (Pubitemid 14223246)
23. Rhodes DG, Sarmiento JG, and Herbette LG (1985) Kinetics of binding of membraneactive drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1, 4-dihydropyridine calcium channel antagonists to their active site. Mol Pharmacol 27:612-623. (Pubitemid 15010692)
24. Sargent DF and Schwyzer R (1986) Membrane lipid phase as catalyst for peptidereceptor interactions. Proc Natl Acad Sci USA 83:5774-5778. (Pubitemid 16000594)
25. Sykes DA, Dowling MR, and Charlton SJ (2009) Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76:543-551.
26. Sykes DA and Charlton SJ (2012) Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists. Br J Pharmacol 165:2672-2683.
27. Szczuka A, Wennerberg M, Packeu A, and Vauquelin G (2009) Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol. Br J Pharmacol 158:183-194.
28. Valko K, Du CM, Bevan CD, Reynolds DP, and Abraham MH (2000) Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. J Pharm Sci 89:1085-1096.
29. Vauquelin G (2010) Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin Drug Discov 5:927-941.
30. Vauquelin G and Packeu A (2009) Ligands, their receptors and... plasma membranes. Mol Cell Endocrinol 311:1-10.
31. Vauquelin G and Charlton SJ (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161:488-508.